Evidence map›Paper›PMID 37492112›Full record

ArticleKidney medicine2023

Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada.

Jeffrey T Ha, Anish Scaria, Jason Andrade, Sunil V Badve, Peter Birks, Sarah E Bota, Anna Campain, Ognjenka Djurdjev, Amit X Garg, Ziv Harel and 15 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07098078 (Domperidone Dose and the Risk of Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07098078 completednot on this map

Domperidone Dose and the Risk of Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease: A Population-Based Cohort Study Research Protocol

TypeobservationalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2008 to 2024Enrolled15,000ConditionsChronic Kidney Disease (CKD)ArmsDomperidone (drug)
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Comparative safety of oral anticoagulants in severe renal impairment.Research and practice in thrombosis and haemostasis · 2026
    Article
  5. Article
  6. Article
  7. Innovations in pharmacovigilance studies of medicines in older people.British journal of clinical pharmacology · 2025
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 3 countries.

Jeffrey T HaThe George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.
Anish ScariaThe George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.
Jason AndradeUniversity of British Columbia, Vancouver General Hospital, Vancouver, British Columbia, Canada.
Sunil V BadveThe George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.
Peter BirksUniversity of British Columbia, Vancouver General Hospital, Vancouver, British Columbia, Canada.
Sarah E BotaICES, Ontario, Canada.
Anna CampainThe George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.
Ognjenka DjurdjevBC Provincial Renal Agency, Vancouver, British Columbia, Canada.
Amit X GargICES, Ontario, Canada.
Ziv HarelDivision of Nephrology, St. Michael's Hospital, Toronto, Ontario, Canada.
Brenda HemmelgarnFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Carinna HockhamThe George Institute for Global Health, U.K., Imperial College London, London, United Kingdom.
Matthew T JamesCumming School of Medicine, Division of Nephrology, University of Calgary, Alberta, Canada.
Meg J JardineNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Dickson LamThe George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.
Adeera LevinUniversity of British Columbia, Vancouver General Hospital, Vancouver, British Columbia, Canada.
Eric McArthurICES, Ontario, Canada.
Pietro RavaniCumming School of Medicine, Division of Nephrology, University of Calgary, Alberta, Canada.
Selena ShaoBC Provincial Renal Agency, Vancouver, British Columbia, Canada.
Manish M SoodThe Ottawa Hospital Research Institute and Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
Zhi TanCumming School of Medicine, Division of Nephrology, University of Calgary, Alberta, Canada.
Navdeep TangriDepartment of Internal Medicine, University of Manitoba, Max Rady College of Medicine, Winnipeg, Manitoba, Canada.
Reid WhitlockDepartment of Internal Medicine, University of Manitoba, Max Rady College of Medicine, Winnipeg, Manitoba, Canada.
Martin GallagherThe George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.
Min JunThe George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.
UNSW Sydney · AUUniversity of British Columbia · CAUniversity of Calgary · CASeven Oaks General Hospital · CALiverpool Hospital · AUOttawa Hospital · CASt. Michael's Hospital · CAThe George Institute for Global Health · GBThe University of Sydney · AUUniversity of Alberta · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale & Objective: The benefit-risk profile of rivaroxaban versus warfarin for atrial fibrillation (AF) in patients with chronic kidney disease is uncertain. We compared rivaroxaban with warfarin across the range of kidney function in adults with AF. Study Design: Multicenter retrospective cohort. Setting & Participants: Adults with AF and a measure of estimated glomerular filtration rate (eGFR); using administrative data from 5 jurisdictions across Australia and Canada (2011-2018). Kidney function was categorized as eGFR ≥60, 45-59, 30-44, and <30 mL/min/1.73 m Exposures: New dispensation of either rivaroxaban or warfarin. Outcomes: Composite (1) effectiveness outcome (all-cause death, ischemic stroke, or transient ischemic attack) and (2) major bleeding events (intracranial, gastrointestinal, or other) at 1 year. Analytical Approach: Cox proportional hazards models accounting for propensity score matching were performed independently in each jurisdiction and then pooled using random-effects meta-analysis. Results: 55,568 patients (27,784 rivaroxaban-warfarin user matched pairs; mean age 74 years, 46% female, 33.5% with eGFR <60 mL/min/1.73 m Limitations: Unmeasured treatment selection bias and residual confounding. Conclusions: In adults with AF, rivaroxaban compared with warfarin was associated with lower or similar risk of all-cause death, ischemic stroke and transient ischemic attack and similar risk of bleeding across a broad range of kidney function. Plain-Language Summary: This real-world study involved a large cohort of 55,568 adults with atrial fibrillation from 5 jurisdictions across Australia and Canada. It showed that the favorable safety (bleeding) and effectiveness (stroke or death) profile of rivaroxaban compared with warfarin was consistent across different levels of kidney function. This study adds important safety data on the use of rivaroxaban in patients with reduced kidney function, including those with estimated glomerular filtration rate <30 mL/min/1.73 m

Indexed as

Atrial fibrillationbleedingchronic kidney diseasedeathdirect oral anticoagulanteGFRrivaroxabanstrokewarfarin

Identifiers

PMID37492112
PMCPMC10363562
OpenAlexW4377042267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.